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OBJECTIVES: In real practice, patients are treated along the entire year so that
budget simulations should be adjusted to chronological patterns of oncological
assistance. Deferred budget impact analysis is undergone in order to assess long-
run economic implications of clinical decisions on first-line mCRC therapies in
Spain. METHODS: As metastatic colorectal cancer diagnosis is not affected by sea-
sonal influences, we have created a mathematical model assuming that a single
patient is diagnosed every month and this patient has a 53% possibility to harbor a
native K-Ras sequence. Calculi were arranged based on median duration of ther-
apy. For bevacizumab-based therapy, budget impact for year t1 begins at month
5 and beyond. For patients that receive cetuximab-based therapy, budget impact
for year t1 begins at month 7. The same approach was performed for doublets
without any monoclonal antibody. Prices for all drugs in Spain were assumed to
represent the best-value for each drug including all possibilities to reduce phar-
macy costs. For first line, median duration of therapy reported by randomized trials
was used to calculate the final budget. 70kg and 1.7 m were used as reference for
patient dose calculations. RESULTS: When K-Ras status is not tested and bevaci-
zumab-based schedules are administered to every patient, annual growth of bud-
get increases by 55-60%. If K-Ras status is analyzed and wild-type patients are
treated with cetuximab combinations and mutated patients receive bevacizumab,
yearly budget growth amounts to 39-41%. Annual budget growth is minimized
(25%) when K-Ras wt patients are treated with cetuximab combinations whereas
K-Ras mutated tumours received chemotherapy alone. CONCLUSIONS: Duration
of therapy plays a key role on budget impact estimations from both overall and year
to year perspectives. K-Ras based clinical decisions not only optimize outcomes as
measured by response rates but also minimize economic implications on annual
budget growths.
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OBJECTIVES: Immunonutrition (IN) with arginine has been demonstrated in many
randomized clinical trials (RCTs) to decrease the risk of complications and the
length of hospital stay (LOS) in cancer patients undergoing gastrointestinal (GI)
surgery (Cerantola et al. 2011). This study aims at assessing the cost-effectiveness
of IN for upper GI cancer patients undergoing surgery in the National Health Sys-
tem (NHS). METHODS: Clinical data were retrieved from the meta-analysis of Cer-
antola. Both the decrease in LOS due to IN and the relative risk (RR) of overall
complications (Chevrou-Severac et al, 2011) were taken into account. Hospital cost
data (upper GI cancer surgical patients) were extracted from the Healthcare Re-
source Group codes of the NHS Payment by Results 2011/12 and Hospital Episode
Statistics. The cost of stay based on the LOS for the IN and the control group were
calculated. Finally a sensitivity analysis of the baseline (control group) complica-
tion rate was carried out. RESULTS: The RR of overall complications were 0.69 for
pre-operative and 0.62 for peri-operative use of IN. The hopspital LOS decreased by
2.42 days ifor pre- and 1.63 days for peri-operative use of IN. Weighted national
average hospital cost (GI cancer surgey) was £829 per day. Weighted national av-
erage cost of stay for patients with complications was £9,766 per patient and £5,421
per patient without complications. Based on the LOS decrease, IN is cost-savings in
upper GI surgery compared to control (savingsf £1,955 to £1,093 per patient). Even
for an initial complication rate as low as 5% in the control group, pre-operative use
of IN led to savings. CONCLUSIONS: Immunonutrition is an effective and cost-
saving intervention for the NHS: savings up to £1,955 per patient-stay with pre-
operative use of IN. Immunonutrition in patients undergoing surgery for upper GI
cancer is an efficient intervention for British hospitals, as it decreases LOS, post-
surgical complications and hospital costs.
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OBJECTIVES: Image-Guided Radiation Therapy (IGRT) is an innovative technique
allowing three-dimensional control of the position of the anatomical target vol-
umes before or during sessions of irradiation. In case of prostate cancer, IGRT
allows clinicians to localize the tumor, either with Cone Beam Computed Tomog-
raphy (CBCT) or by portal imaging with Fiducial Markers (FM). A weekly positioning
control is generally carried out. However, daily controls has been recommended in
case of Intensity-Modulated Radiation Therapy (IMRT) delivering high dose in the
prostate. Therefore, a cost analysis investigating IGRT with CBCT and FM according
to the positioning frequency daily versus weekly in prostate cancers was
conducted. METHODS: The cost-analysis was performed in a multicenter random-
ized phase III trial. Patients included received radiotherapy for a localized prostate
adenocarcinoma. Cost calculations were strictly based on a micro costing approach
according to the hospitals’ point of view. Time horizon included radiation therapy.
All costs were given in 2009 euros. Comparisons were performed using Wilcoxon
Mann-Whitney test. Uncertainty was captured by one-way sensitivity analyses
and probabilistic analysis using a non-parametric bootstrap method. RESULTS: A
total 208 patients were enrolled in seven French centres from January 2007 to May
2011. Protocol deviations reduced the number of patients included in the study to
183. For CBCT, the over cost of daily positioning controls (n67) reached €679 per
patient, compared to weekly controls (n61, p0.0001). For FM, the over cost of
daily positioning controls (n26) reached €187 per patient compared to weekly
controls (n29, p0.0001). Variations in depreciation periods of the accelerator and
time spent by radiotherapists have the highest impact on costs. CONCLUSIONS:
The study highlights incremental costs incurred by different frequencies of posi-
tioning with IGRT in prostate cancers. Cost-effectiveness studies have to be con-
ducted in order to shed further light on which strategy to focus on based on clinical
benefit.
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OBJECTIVES: Companion diagnostics (CD) is a new approach to personalised med-
icines for safer and more efficacious selection of treatments. This review was con-
ducted for cost assessment of CDs in breast cancer (BC). METHODS: Embase® and
MEDLINE®databases were systematically searched until June 2012 to identify eco-
nomic studies on CDs in BC. All economic studies in English language, regardless of
design and diagnostic test assessed were included. Eligibility of studies was as-
sessed by two reviewers with any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 202 studies were retrieved; 24 met pre-defined inclu-
sion criteria. Fifteen studies assessed cost of Oncotype Dx, three Mammaprint, two
HercepTest, one IHC, and three both Oncotype Dx and Mammaprint tests. An Irish
study reported that an approximate cost-neutrality (0.4% increase in cost) to its
health care system on adoption of Oncotype DX test (Lacey 2010). Another study in
Canada reported that the introduction of Oncotype DX would result in cost saving
of $27.0m in first year and $28.2m by third year (Hassan 2011).The ICER for Mam-
maPrint was estimated as ¥3,873,922/QALY exhibiting its cost-effectiveness (Kondo
2012). In Israel, Oncotype Dx increased QALY by 0.170 years with $10,770/QALY
gained by reducing the chemotherapy disutility (Klang 2010). In Australia, cost
savings due to reduction in chemotherapy due to Oncotype Dx was estimated to be
$2264/woman. The cost of assay was estimated to be $4200 with a published utility
rate of 0.5, resulting in ICER of $9986/QALY compared without diagnostic test
(O’Leary 2010). CONCLUSIONS: The findings from the published data reflects that
CDs were cost-effective and demonstrated quality of life and survival benefits of a
more targeted approach to treatment decision-making. Literature is suggestive
that using a personalised approach through initial diagnostic tools for BC can help
in reduction of chemotherapy usage and cost savings in health care services.
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OBJECTIVES: Due to the increasing cost pressure, it is necessary to rely on cost-
effective-therapies. Currently there are three monoclonal antibodies (Bevaci-
zumab, Panitumumab, Cetuximab) in the treatment of colorectal cancer, which
differ in their cost structure. Thus, this study aims to compare the costs of ap-
proved therapies from the hospital perspective. METHODS: The cost analysis in-
cludes all direct resources in the course of medication therapy. All relevant direct
medical costs associated with the treatment were detected and quantified: drug
costs of the antibodies, medical consumables, personnel costs and KRAS-testing.
Furthermore, the number-needed-to-treat (NNT) for the three alternatives was
calculated. Additionally, based on the total costs, a cost-effectiveness-depiction
represents the additional costs of the overall-survival (OS) per month. RESULTS:
The absolute benefit of the add-on-therapy leads to a longer progression-free-
survival (PFS) in the treatment-group compared to the control-group. The relative
superiority in PFS for Bevacizumab is 82.4%, 17.9% for Cetuximab and 20% for
Panitumumab. Based on the PFS, the NNT for Bevacizumab accounts for 2 patients,
6 for Cetuximab and 5 for Panitumumab vs. the control-group. According to the
frequency of the number of administrations, the total cost for Bevacizumab
amounts to €2,442.87 per month, €3,693.89 for Cetuximab and €3,671.37 for Panitu-
mumab. The savings of Bevacizumab vs. Cetuximab, based on the total cost, are
€1,251.02 per month. The cost difference of Bevacizumab compared with Panitu-
mumab amounts to €1,228.50 per month. Based on the indirect comparison trial
(ITC), the monthly costs per OS for Bevacizumab amounts to €1,035.19 compared
with Cetuximab (€1,611.55) and Panitumumab (€1,609.19). With regard to the over-
all treatment, the cost savings amounts to €7,581.58 for Bevacizumab compared to
Cetuximab and for Panitumumab €8,719.54. CONCLUSIONS: The presented data of
the cost-comparison-analysis for the approved antibodies therapy are able to dem-
onstrate the possible potential savings through the therapy with Bevacizumab.
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OBJECTIVES: To evaluate the cost-effectiveness of prescribing branded
Taxotere®compared to its generic counterpart docetaxel for patients diagnosed
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with breast cancer in the UK NHS. METHODS: A previously published decision tree
model was populated and developed with the Vial et. al. and Brown et. al. trial data
to assess the cost-effectiveness of using branded Taxotere®versus its generic coun-
terpart docetaxel from the UK NHS perspective. RESULTS: If the branded Taxotere®
was promoted as the first-line therapy, it would cost the UK NHS £411.54 per vial
per patient with 0.434 QALY (Quality-Adjusted Life Years) gain compared to £412.98
with 0.418 QALY gain if the generic docetaxel was promoted instead and failed the
therapy. Although the acquisition cost of docetaxel is more than 50% less than that
of Taxotere®, promoting the generic docetaxel based on its lower acquisition cost,
only, would result in increasing the total health care cost compared to Taxotere®.
CONCLUSIONS: Based on the decision tree model generated in this study, promot-
ing the branded Taxotere® is more cost-effective compared to its generic counter-
part docetaxel. This should be considered for implementation in practice and for
future guidelines.
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OBJECTIVES: To estimate which is the dominant treatment between the only two
drugs that had been able to demonstrate overall survival (OS) improvements in
patients with metastatic castrate resistant prostate cancer (mCRPC) that have pro-
gressed on or after docetaxel treatment, and that were approved by the EMA in 2011
(AA by accelerated procedure): cabazitaxel (CBZ) and abiraterone acetate (AA),.
METHODS: We replicated the methodology most commonly used by Spanish hos-
pitals to estimate the cost-efficacy of oncologic drugs (OS gains and incremental
costs vs. those of comparators) by: (i) taking the perspective of the Spanish NHS (ii)
estimating treatment costs based on the product labels (i.e. main medication, co-
medication, premedication, and primary prophylaxis) at ex-factory prices, and the
cost of administering such medications; and (iii) the OS data from the respective
pivotal phase III trials: for CBZ vs. mitoxantrone prednisone (MP) OS was 15.1 vs.
12.7 months. For AA vs. placebo prednisone (PP) OS was 15.8 vs. 11.2. Input for the
base case analysis comes from Phase III randomized clinical trials and from pub-
licly available cost data. Sensitivity analysis was performed on: (i) length of treat-
ment; (ii) median OS; and (iii) G-CSF usage and drug administration costs.
RESULTS: In our base case scenario the cost per cycle of CBZ was 4,711.52€ vs.
78.20€ for MP. The cost per cycle of AA was 3,179.26€ vs. 11.85€ for PP. Treatment
costs difference for CBZ vs. MP is 27,799.93€ (range 13,665.36€ – 46,646.01€) and for
AA vs. PP is 25,386.71€ (range 12,669.65€ - 38,103.76€). OS gain is 2.4 months for CBZ
and 4.6 months for AA. CONCLUSIONS: In Spain, based on local hospital method-
ology, AA would be the dominant alternative (higher OS gain and lower incremen-
tal cost) to treat mCRPC patients that have progressed on or after a docetaxel based
regime.
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OBJECTIVES: In Germany, health economic studies are increasingly based on
health insurance claims data analysis. Such data offer a wide range of scientific
applications, especially when focusing on the assessment of resource utilization
patterns and costs. The objective of our study was to estimate the direct health care
costs of three frequent types of cancer (colorectal, breast, and prostate cancer) from
a third-party payer perspective using longitudinal data from a German statutory
health insurance fund and employing a matched pairs design. METHODS: Our
analysis is based on administrative data of a German sickness fund covering a
5-year period (2005-2009). A total of 42,085 cancer patients were included. Disease-
specific costs were estimated by matching cancer patients to counterparts without
the particular condition and subsequently comparing the costs of the two groups.
One-to-one matching was performed by application of the propensity score
method to balance patient characteristics among the cancer groups and non-can-
cer controls. The cost categories considered in this study included prescription
drug costs, outpatient visit costs, and hospitalization costs. RESULTS: The mean
cancer-associated 5-year costs per patient amounted to €5,429 for colorectal can-
cer, €3,200 for breast cancer, and €5,350 for prostate cancer. The average disease-
attributable costs of the first year following diagnosis were €8,750, €4,300, and
€4,750 for colorectal, breast and prostate cancer, respectively. Corresponding ex-
cess costs of the last year of life were €15,900, €10,950, and €14,750. Costs associated
with hospitalization accounted for a major part of the total disease-specific costs
(up to 80%). CONCLUSIONS: This cost-of-illness study based on claims data anal-
ysis confirms the high economic burden of colorectal, breast, and prostate cancer.
Most of the costs occurred in the initial and terminal treatment phases. Inpatient
treatment was found to be the main cost driver.
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Incidence of penile cancer in Europe is slightly increasing. Survival rates in penile
cancer are good, however, there is little research into treatment costs.OBJECTIVES:
To estimate the cost of treating penile cancer in English hospitals, using data from
the HES database. This investigation is part of a wider project aimed at quantifying
the total economic burden of penile cancer in the UK. METHODS: Inpatient admis-
sions for penile cancer between the years 2006/07 to 2010/11 were retrospectively
analysed. Data was obtained from HES, a database covering English hospital activ-
ity, with inpatient episodes aggregated into spells of care associated with a specific
Healthcare Resource Group (HRG). The HRGs were linked to costs from the UK
National Tariff in order to calculate the average annual and per patient payments
for inpatient treatment of penile cancer, as per the NHS Payment by Results frame-
work. Where necessary, costs were supplemented by expert opinion and other
published cost estimates. A limited amount of HES data on outpatient consulta-
tions was also collected and analysed. RESULTS: The mean annual amount paid to
English hospitals for inpatient treatment of invasive penile cancer in England was
estimated to be £2,391,700, with a further £189,106 paid for carcinoma in situ of the
penis. Per inpatient, mean costs were approximately £3,743 and £1,323 for invasive
penile cancer and carcinoma in situ, respectively. Outpatient costs were consider-
ably lower, due to the majority of care being delivered in an inpatient setting and
issues with HES outpatient data collection. Further research into outpatient costs is
currently ongoing. CONCLUSIONS: The burden of penile cancer in the UK has cost
implications, the full extent of which cannot yet be ascertained due to underesti-
mation of outpatient costs. Any preventive intervention aimed at decreasing this
burden should be carefully considered.
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OBJECTIVES: To estimate the costs associated with melanoma for Russia in 2009.
METHODS: Prevalence-based cost-of-illness analysis (COI) was performed from
the payer’s point of view (national and regional governments). Direct medical costs
(hospital and outpatient services and drugs provided in outpatient care), non-med-
ical costs (monetary payments in social benefits) and indirect costs (projected pro-
ductivity loss due to sickness and disability) associated with melanoma in Russia in
2009 were calculated. We obtained the data for analysis from the national statis-
tics, regional cancer and prescription registries, expert panel interviews and liter-
ature. The costs were calculated for the total population of melanoma patients in
Russia. To calculate direct medical costs, we used national reimbursement rates
per unit of care (1 hospital day or 1 visit to an out-patient oncology clinic) and
regional data on melanoma drug costs. To access non-medical costs, we used data
on social benefits expenditures. Indirect costs were estimated with friction costs
method. RESULTS: The total costs of melanoma in Russia in 2009 was 771,2 million
RUR (€18,8mln), or 11 314 RUR (€275,9) as average cost per patient per year. Almost
half of total costs (48.3%) occur in patients during the 1st year after diagnosis. The
direct medical costs accounted for 52,41% of total spending, direct non-medical
costs – for 34,9%, and indirect costs – for 12,69%. Direct medical costs represented
72,8% of total spending in melanoma patients within the 1st year after the diagno-
sis; during the subsequent years after the diagnosis this number reduces to 34,2%.
CONCLUSIONS: Our analysis demonstrates that the most significant part of med-
ical costs for melanoma occur during the 1st year after diagnosis that corresponds
with the results of other COI studies in oncology; in subsequent years the main
costs are outside the scope of health care system.
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OBJECTIVES:Despite the considerable disease burden of ovarian cancer (OC), there were
no cost studies in Central and Eastern Europe. This study aimed to describe treatment
patterns, health care resource utilization and costs associated with OC in Hungary, Po-
land, Serbia and Slovakia. METHODS: Overall clinical practice for management of
epithelial ovarian cancer was investigated through a three-round Delphi panel
consisting of 15 clinical experts. Experts completed a survey based on patient re-
cords (N1,542). The survey was developed based on clinical guidelines and the
FIGO Annual Report. Means, ranges and outlier values were discussed with the
experts during a telephone interview. Finally, consensus estimates were obtained
in face-to-face workshops. Based on these results, overall cost of OC was estimated
using a Markov model. RESULTS: The patients included in the chart review were
followed from pre-surgical diagnosis and in each phase of treatment, i.e. primary
surgical staging and surgery, chemotherapy and chemotherapy monitoring, fol-
low-up and palliative care. Overall treatment patterns were similar but regimens in
second and subsequent lines of chemotherapy varied across the countries. The
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